ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Also Weber returns to M.D. Anderson.

August 8, 2003

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

NTP Board Gives Concept Approvals

December 4, 1981

Platinum-Free Break Enhances Therapy After First Relapse In Ovarian Cancer

March 28, 2003

DCT Advisors Approve Grants Program For Trials Of BRMs

March 10, 1995

In Congress: HHS Hasn’t Identified Another Source For NIH Increase If Tobacco Bill Not Passed: Shalala

March 6, 1998